In urine drug testing, enantiomer analysis is used to determine whether a positive methamphetamine result could be due to use of an over-the-counter (OTC) nasal inhaler containing L-methamphetamine. D-methamphetamine at more than 20% of the total is considered indicative of a source other than an OTC product. This interpretation is based on a 1991 Department of Health and Human Services (HHS) Technical Advisory. We performed studies to verify the methamphetamine enantiomer content of current OTC nasal inhalers and to evaluate current laboratory testing capabilities. This study demonstrated that OTC inhalers contain less than 1% D-methamphetamine. A proficiency testing (PT) set for HHS-certified laboratories performing methamphetamine enantiomer testing found D-methamphetamine percentages that were consistently 1 to 3% higher than theoretical due to optical impurity of the derivatizing reagent N-trifluoroacetyl-L-prolyl chloride (L-TPC). The PT results also demonstrate that laboratories can accurately determine 20% D-methamphetamine in samples with total methamphetamine concentrations down to 250 ng/mL. Based on these studies, the guideline of >20% D-methamphetamine is appropriate for interpreting results obtained using current laboratory methods.
Introduction
In urine drug testing conducted in accordance with the Department of Health and Human Services (HHS) Mandatory Guidelines for Federal Workplace Drug Testing Programs (1) , it is the responsibility of the Medical Review Officer (MRO) to interpret a positive methamphetamine drug test result. If a donor denies the use of methamphetamine, but claims to have used an over-the-counter (OTC) nasal inhaler (e.g., Vicks w VapoInhaler), the MRO should order methamphetamine enantiomer testing to delineate the enantiomeric composition. Amphetamine and methamphetamine enantiomer testing is optional for HHS-certified laboratories. At the time of these studies, 24 of the 37 HHS-certified laboratories performed methamphetamine enantiomer testing.
HHS guidance to MROs (2) for interpreting methamphetamine enantiomer test results is as follows. If there is .80% L-methamphetamine, the results are consistent with OTC inhaler use. If there is .20% D-methamphetamine present, the results indicate a source other than an OTC product, and the test result is verified as positive for methamphetamine. These percentages, provided to HHS-certified laboratories in a 1991 HHS Technical Advisory (3) , are considered to be very conservative interpretive guidelines.
Revisions to the HHS Mandatory Guidelines included lowering the methamphetamine confirmatory test cutoff from 500 to 250 ng/mL. After the lower cutoff was implemented (effective October 1, 2010), some MROs reported an increase in the number of methamphetamine positive results with percentages of D-methamphetamine ,20% (4) . In some of these cases, the total methamphetamine concentration was .5,000 ng/mL, with L-methamphetamine well above the 1,390 ng/mL maximum reported from nasal inhaler use (5) . Additionally, there have been reports of clandestine methamphetamine containing low amounts of D-methamphetamine (6) along with steps to reduce the availability of ephedrine and pseudoephedrine (7) often used in the production of illicit methamphetamine.
These factors prompted the Substance Abuse and Mental Health Services Administration (SAMHSA) to direct studies by RTI International (RTI) to evaluate the testing capabilities of HHS-certified laboratories and to reassess the current HHS interpretation guidance. We designed studies to (i) determine the amount of methamphetamine enantiomers in OTC nasal inhalers, (ii) determine the purity of commercial methamphetamine enantiomer standards, and (iii) prepare and evaluate results of a methamphetamine enantiomer proficiency testing (PT) set to determine the lowest concentration and lowest percentage of D-methamphetamine that HHS-certified laboratories could accurately quantify.
Methods

Materials
Both D-and L-methamphetamine were purchased from Grace Davidson Discovery Sciences (Deerfield, IL) and Sigma-Aldrich (St. Louis, MI). The certificate of analysis for each of the four compounds stated the purity to be .97%. Six OTC nasal inhalers were purchased from various pharmacies in the Research Triangle Park, NC area: three Vicks w VapoInhalers with different lot numbers and three pharmacy store brand inhalers (i.e., Walgreens, CVS and Kerr). The product ingredient labels listed 50 mg "levmetamfetamine," a pseudonym for L-methamphetamine. Methanol (HPLC grade) was purchased from EMD Chemicals (Gibbstown, NJ). Disposable scintillation vials (20 mL) were purchased from VWR (Atlanta, GA).
Nasal inhaler preparation
The plastic cylinder of each inhaler was sliced open and the swab containing the drug was removed. Each swab was immersed in 10 mL of methanol in separate, capped scintillation vials and mechanically rocked for one hour. One mL of each methanolic solution was diluted 1:1,000 with deionized water to a theoretical L-methamphetamine concentration of 5,000 ng/mL (based on 50 mg of L-methamphetamine per package insert). At this dilution, a 1% contamination of D-methamphetamine would be at 50 ng/mL, the limit of quantitation (LOQ) for the two HHS-certified laboratories analyzing these samples.
Standard solution preparation
The two D-methamphetamine drug standards obtained from different chemical suppliers were weighed and diluted with deionized water to final stock solution concentrations of 4,800 ng/mL. Two stock solutions of L-methamphetamine were prepared in the same manner, to provide final concentrations of 5,200 ng/mL. All four stock solutions were tested by four HHS-certified laboratories before they were used to prepare the PT samples.
PT sample preparation Drug-free human urine was collected from volunteers using protocols of RTI's Institutional Review Board. This urine was fortified with D-and L-methamphetamine stock solutions to produce 18 homogeneous PT sample lots, each with a volume of 2,000 mL. Samples of each lot were prepared by dispensing 35 mL of urine into a 125 mL high-density polyethylene (HDPE) bottle. A PT set containing 18 samples (one of each lot) was shipped to each of the 24 HHS-certified laboratories performing methamphetamine enantiomer testing. D-methamphetamine target concentrations ranged from 0 to 1,000 ng/mL (lowest spiked concentration of 25 ng/mL) and L-methamphetamine from 0 to 4,750 ng/mL (lowest spiked concentration of 75 ng/mL). These samples provided challenges containing D-methamphetamine percentages that ranged from 0 to 100% with emphasis on 5 to 20% (11 of the 18 samples).
Laboratory testing
At the time of the studies, 24 of 37 HHS-certified laboratories performed methamphetamine enantiomer testing (three laboratories also performed amphetamine enantiomer testing). All 24 laboratories used gas chromatography-mass spectrometry (GC-MS) with a chiral derivatizing reagent for their enantiomer assay. Twenty-three laboratories used N-trifluoroacetyl-L-prolyl chloride (L-TPC) and one laboratory used (R)-(-)methoxytrifluoromethylphenylacetic acid (MTPA) as the chiral derivatizing reagent for enantiomer testing. The methamphetamine enantiomer LOQ values at the time were 100 ng/mL (one laboratory), 50 ng/mL (11 laboratories), 40 ng/mL (two laboratories), 25 ng/mL (three laboratories) and not determined (seven laboratories). Fourteen of the 24 laboratories determined enantiomer percentages using chromatographic peak areas, with the formula %D-methamphetamine ¼ D-methamphetamine peak area 4 (D-methamphetamine þ L-methamphetamine peak areas) Â 100%. The remaining 10 laboratories quantified D-and L-methamphetamine using internal standards and then determined percentages using the calculated concentrations.
Two of the laboratories (designated Laboratory A and Laboratory B) participated in the study to determine OTC nasal inhalers' methamphetamine enantiomer content. Laboratory A analyzed each solution twice, in separate batches, using the L-TPC chiral derivatizing reagent. Laboratory B analyzed each solution once using the MTPA derivatizing reagent. Laboratory A also analyzed each solution for D-and L-amphetamine. In addition, Laboratory A quantified the total amount of methamphetamine for each inhaler solution using their routine amphetamines confirmatory procedure. RTI then calculated the amount of drug on each tested swab.
Four laboratories participated in the standard solution study to determine the purity of purchased enantiomer standards. These included Laboratories A and B from the inhaler study and two other laboratories designated as Laboratories C and D. Each laboratory analyzed the four standard solutions. Laboratories A, C and D used the chiral reagent L-TPC, while Laboratory B used MTPA.
The 24 laboratories tested all PT samples using their amphetamines immunoassay initial test, amphetamines GC -MS confirmatory test, and D-and L-methamphetamine enantiomer test. For each PT sample, the laboratories reported the D-and L-methamphetamine percentages, D-and L-methamphetamine peak areas and D-and L-methamphetamine concentrations (if internal standards were used). RTI used the peak areas or enantiomer concentrations to verify the reported enantiomer percentages. Table I presents the D-methamphetamine results from Laboratories A and B for the methanolic solutions prepared from the six inhalers. As noted previously, Laboratory A analyzed each solution twice, in separate batches, using the L-TPC chiral derivatizing reagent. This laboratory reported average D-methamphetamine percentages of 2 to 2.5% for all six inhalers. Laboratory B analyzed each solution once using the MTPA derivatizing reagent, and reported 0% D-methamphetamine for each of the six inhalers. A technical representative from Proctor and Gamble verified by telephone that the percentage of D-methamphetamine in the Vicks w VapoInhaler is ,1%. Although data are not included in Table I , Laboratory A found no D-and L-amphetamine in the six inhalers.
Results and Discussion
Nasal decongestant inhalers
We calculated the amount of drug on each tested swab from the total methamphetamine results reported for each inhaler solution by Laboratory A from its amphetamines confirmatory GC-MS procedure. Although each inhaler package was labeled to contain 50 mg of drug, total methamphetamine was determined to be: Vicks w VapoInhaler lot 1 (68 mg); Vicks Standard solutions Average D-methamphetamine percentages for the standard solutions are presented in Table II . Each laboratory obtained similar results for the standard solutions from both suppliers (i.e., within-laboratory results were not statistically significant).
The three laboratories using the L-TPC derivative (Laboratories A, C and D) found between 95.5 and 97.7% D-methamphetamine in the D-methamphetamine solutions, and between 2.3 and 3.5% D-methamphetamine in the L-methamphetamine solutions. However, the laboratory using the MTPA derivative (Laboratory B) found the D-methamphetamine solutions and the L-methamphetamine solutions to be 100% pure.
D-,L-Methamphetamine proficiency testing set
On June 27, 2011, a set of 18 PT samples was sent to the 24 HHS-certified laboratories that perform methamphetamine enantiomer testing. As described previously, each laboratory tested all PT samples using their amphetamines immunoassay initial test, amphetamines GC-MS confirmatory test, and Dand L-methamphetamine enantiomer test. The objective of immunoassay testing was to determine the amphetamines immunoassays' cross-reactivity to L-methamphetamine at different concentrations. This information would help assess the likelihood of donor specimens with L-methamphetamine from the use of OTC inhaler testing positive by initial testing and being reflexed to confirmatory testing. The analytical objectives of the PT quantification study were to determine the lowest concentration and lowest percentage of D-and L-methamphetamine that these laboratories were capable of accurately quantifying. These data allow evaluation of the .20% D-methamphetamine guidance for identifying non-OTC use. In addition, the purpose of amphetamines confirmatory testing was to determine whether total methamphetamine concentrations were consistent with the sums of D-and L-methamphetamine concentrations determined by laboratories quantifying the enantiomers.
Immunoassay study
The amphetamines immunoassay initial test cutoff for federal workplace testing is 500 ng/mL, with D-methamphetamine as the target analyte (1). As presented in Table III , the eight PT samples containing 0 to 100 ng/mL D-methamphetamine in combination with 50 to 500 ng/mL L-methamphetamine were immunoassay negative. One PT sample (#6) containing only D-methamphetamine targeted at 500 ng/mL (mean ¼ 489 ng/ mL) was immunoassay positive at 11 of 24 laboratories, which was expected because the target concentration was at the cutoff. PT samples (#13, #14 and #15) with target D-methamphetamine concentrations of 250, 500 and 1,000 ng/ mL and L-methamphetamine of 4,750, 4,500 and 4,000 ng/mL, respectively, were immunoassay positive by all laboratories. These results demonstrate the cross-reactivity of higher concentrations of L-methamphetamine in the presence of D-methamphetamine below the cutoff (PT #13) or at the cutoff (PT #14).
One PT sample (#16) was prepared to mimic nasal inhaler use. The PT sample contained 1,000 ng/mL L-methamphetamine and 150 ng/mL L-amphetamine (i.e., a metabolite of L-methamphetamine). Sixteen of the 17 laboratories using the Siemens EMIT II amphetamines reagent obtained a positive immunoassay result. Laboratories using other reagents obtained negative results for the sample (i.e., three laboratories used CEDIA, two used KIMS, one used DRI and one used CEDIA Amphetamines/Ecstasy). A similar PT sample containing 4,000 ng/mL of L-methamphetamine and 150 ng/mL of L-amphetamine tested positive at all 17 laboratories using the Siemens reagent and at the laboratory using the CEDIA Amphetamines/Ecstasy reagent. These data reveal that the reagent used by the majority of HHS-certified laboratories (Siemens EMIT II amphetamines reagent) cross-reacts with L-methamphetamine. Therefore, use of OTC nasal inhalers may cause immunoassay-positive results.
PT samples #10, #11 and #12 had L-methamphetamine concentrations of 950, 900 and 800 ng/mL and D-methamphetamine concentrations of 50, 100 and 200 ng/mL, respectively. Only laboratories using the Siemens reagent reported these three samples positive. These data further demonstrate the sensitivity of the Siemens EMIT II amphetamines reagent to L-methamphetamine.
Quantification study
Objectives of this study were to determine the lowest concentration and lowest percentages of D-and L-methamphetamine that HHS-certified laboratories were capable of accurately quantifying. Additionally, the results would help to assess how Tables IV through IX summarize the D-methamphetamine percentage results. The %D-methamphetamine group mean includes all reported percentages. Some laboratories did not report a percentage when the D-methamphetamine concentration was less than the laboratory's LOQ. The following was noted:
(i) PT sample #6 containing only D-methamphetamine had a group mean of 96% D-methamphetamine and a reported range of 87 to 100% (only three results of 100% D-methamphetamine). All laboratories reported correct results in that the D-methamphetamine percentages were within +20% or 2 standard deviations (SD) of the group mean (Table IV) . (ii) PT sample #2 contained equal amounts of D-and L-methamphetamine, with a 50% target for each enantiomer. The target concentration of each enantiomer (50 ng/mL) was the LOQ for 11 of the 24 laboratories. Twenty-one of 24 laboratories reported correct results. Of the remaining three, one laboratory reported a low D-methamphetamine percentage (i.e., outside of the +20% or 2 SD range), and two laboratories did not report a percentage because the D-methamphetamine concentration was less than the laboratory LOQ (Table V) . (iii) Four PT samples (#4, #9, #12 and #15) contained various amounts of D-and L-methamphetamine, with a target ratio of 20% D-methamphetamine. The %D-methamphetamine group means were very similar and were 1.1 to 1.7% higher than the target, including the lowest D-methamphetamine target concentration of 50 ng/mL in PT sample #4. The ranges of reported results for each PT sample were also similar, but with a high bias of the range to the target percentage. One D-methamphetamine percentage was not within +20% or 2 SD of the group mean for each PT sample, and one laboratory reported the percentage as " , 20%" for PT sample #4 because the D-methamphetamine concentration was less than the laboratory LOQ (Table VI) . (iv) Four PT samples (#3, #8, #11 and #14) contained various amounts of D-and L-methamphetamine, with a target ratio of 10% D-methamphetamine. The %D-methamphetamine group means were similar and were 2.1 to 3% above the target. As with the 20% D-methamphetamine samples, the ranges of reported results for each PT sample were nearly the same, but had a high bias. PT sample #8 contained 50 ng/mL of D-methamphetamine, the LOQ of most participating laboratories. Twenty of the 24 laboratories reported correct results for this sample. Of the remaining four, two laboratories had percentage errors and two laboratories reported the PT sample as " , 20%." PT sample #3 had the lowest D-methamphetamine target concentration, 25 ng/ mL. Three laboratories had an LOQ of 25 ng/mL, the lowest LOQ value reported by the participating laboratories. Eighteen of the 24 laboratories reported correct results for this sample. Of the remaining six, one laboratory's reported D-methamphetamine percentage was outside the acceptable range, and five laboratories reported the PT sample as " , 20%" because the D-methamphetamine concentration was below their LOQ (Table VII) . (v) Three PT samples (#7, #10 and #13) contained various amounts of D-and L-methamphetamine, with a target ratio of 5% D-methamphetamine. Again, the %D-methamphetamine group means were 2.5 to 3.4% above the target with high bias ranges. As with the 10% D-methamphetamine samples, 20 of 24 laboratories reported correct results for the 50 ng/mL D-methamphetamine (PT #10) and only 18 laboratories reported correct results for the 25 ng/mL D-methamphetamine sample (PT#7) ( Table VIII) . (vi) Four PT samples (#5, #16, #17 and #18) were prepared with L-methamphetamine of 0 to 4,000 ng/mL and no D-methamphetamine. Of these, the three PT samples containing L-methamphetamine had %D-methamphetamine group means of 2.3 to 2.6%. The reported ranges were 0 to 9%. For PT samples #16 and #17, three laboratories reported D-methamphetamine !5% and for sample #5, four laboratories reported D-methamphetamine percentages !5%. PT #18, which contained no methamphetamine, had a negligible mean percentage of 0.3% D-methamphetamine because one laboratory reported 4.9% D-methamphetamine (Table IX) .
The results of the PT samples targeted to contain 0 to 20% D-methamphetamine consistently demonstrated reported D-methamphetamine group means of 1 to 3% above the expected percentage. This can be attributed to the optical impurity of the L-TPC reagent. Impurities in enantiomer analysis using L-TPC have been reported by others to be 2 to 12% (8, 9) . Additional evidence of L-TPC optical impurity is described in the following, based on a laboratory's investigation of their %D-methamphetamine results more than 20 percent or 2 SD above the group mean percentages for the PT set.
Two of the 24 laboratories consistently reported high D-methamphetamine percentages, with multiple D-methamphetamine percentages outside +20% or +2 SD of the calculated group mean percentages. In their investigations, both laboratories attributed their high bias to the impurity of the L-TPC reagent used in the analyses. One laboratory retested the PT samples along with two in-house controls: one containing 500 ng/mL D-methamphetamine and no L-methamphetamine, and the other containing 500 ng/mL L-methamphetamine and no D-methamphetamine. The laboratory analyzed the samples for %D-methamphetamine using both the old L-TPC reagent (i.e., used in the original analyses of the PT samples) and new L-TPC reagent. The reanalysis results agreed with the PT sample group means, including the high bias exhibited in results obtained by laboratories using L-TPC. Table X summarizes the results of the laboratory's investigation.
Using the old L-TPC reagent, laboratory results for both samples containing 100% L-methamphetamine (i.e., the L-methamphetamine control and PT sample #5) were 6% and 9% D-methamphetamine, respectively. However, with the new L-TPC reagent, the D-methamphetamine percentages were 2%, close to the expected values because the reagent certificate of analysis stated a 1% D-TPC impurity.
Similarly, using the old L-TPC reagent, laboratory results for both samples containing 100% D-methamphetamine (i.e., the D-methamphetamine control and PT sample #6) were 90% D-methamphetamine. However, with the new L-TPC reagent, both were 97%, showing a 3% impurity in the reagent. Table X includes results of a representative sampling of other PT samples with percentages of D-methamphetamine between 5 and 20%, and a total methamphetamine concentration of 500 ng/mL. For these PT samples, the laboratory's original PT results were 7 to 9% above the target D-methamphetamine percentages. On retesting the PT samples with the new L-TPC reagent, the D-methamphetamine percentages showed a 2% deviation above the target value, consistent with the manufacturer's stated reagent impurity of 1%.
Another objective of the quantification study was to determine whether total methamphetamine concentrations were consistent with the sums of D-and L-methamphetamine concentrations determined by laboratories quantifying these enantiomers using isotopic internal standards. For these laboratories, the total methamphetamine concentrations were within +20% of the methamphetamine enantiomer sums for each of the PT samples. The average difference of the total concentration and enantiomer sum was 5.7%. This finding supports the use of internal standards, which is required in routine confirmatory drug testing, in enantiomeric determinations.
Statistical analysis
We investigated the absolute value of the differences between the 0, 5, 10 and 20% D-methamphetamine samples and the %D-methamphetamine reported by each laboratory to determine whether the percentage of D-methamphetamine in a sample affected a laboratory's ability to accurately measure the percentage. There are differences in the laboratories' ability to measure %D-methamphetamine as the percentages change. The mean absolute value of the differences is largest for the 5% sample (2.85) and smallest for the 20% sample (1.87). The mean absolute values of the differences for the 0 and 10% samples are similar to that of the 5% sample (2.47 and 2.50, respectively), suggesting that lower percentages of D-methamphetamine are more difficult for laboratories to accurately measure. We next ran a generalized randomized complete block design (GRCBD) analysis using a general linear model procedure in SAS/STAT software (version 9.2). Based on the PT study design, the laboratories were analyzed as blocks and the PT samples were the replicates in the GRCBD. The overall results for the GRCBD were highly significant (P ,0.0001), indicating that differences exist in the laboratories' ability to measure different percentages of D-methamphetamine. Tukey's Least Significant Difference (LSD) procedure in SAS was used to determine which %D-methamphetamine levels were statistically different. Significant differences between the mean absolute value differences were found between the 20% sample and the other three samples (0, 5 and 10%). No other significant differences were found (Table XI) .
Summary
The statistical analysis of study data reported in this manuscript supports the current guidance for interpreting positive methamphetamine drug test results: .20% D-methamphetamine indicates a source other than an OTC nasal inhaler. This study does not support a change in this guidance at this time using the current laboratory methods. This conclusion is based on the D-methamphetamine group mean percentages for the OTC inhalers, the standard solutions and the PT samples, which revealed biases due to impurities in the chiral derivatizing reagent used by 23 of the 24 HHS-certified laboratories that perform methamphetamine enantiomer analysis.
D-methamphetamine group mean percentages for the OTC inhalers, the standard solutions and the PT samples were 1 to 3% higher than expected for laboratories using the L-TPC reagent when the target was 20% D-methamphetamine, and 3 to 4% lower when the target was !50% D-methamphetamine. These results are consistent with the stated optical purity of the L-TPC chiral derivatizing reagent. The single laboratory using the optically pure MTPA reagent reported results that agreed with the manufacturers' stated content of the nasal inhalers and the manufacturers' stated purity of D-and L-methamphetamine in the standard materials. In addition, only the laboratory using the MTPA reagent reported all 100% L-methamphetamine PT samples (#5, #16 and #17) and the 100% D-methamphetamine PT sample (#6) as 100% pure enantiomers. The caveat with using MTPA is that the chemical damages gas chromatography columns and requires additional maintenance of injector ports and mass selective detectors.
Two options would provide a basis for lowering the current 20% guidance for interpreting methamphetamine enantiomer results from GC -MS assays using chiral derivatization. The first and simplest option would require the testing laboratory to correct the percentage obtained for D-methamphetamine for the amount of impurity in the chiral reagent used for derivatization. As shown in these studies, results obtained with the MPTA reagent would require no correction, because there was no evidence of impurities. The second option would be for laboratories to use a chiral reagent that contained impurities of less than 1%. It is suggested that a chiral reagent other than MPTA be investigated because, as noted previously, the MPTA reagent is corrosive and continued use can damage equipment. 
